Using liquid biopsy from EBUS-TBNA fluid to diagnose lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of analyzing the supernatant fluid from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in diagnosing non-small cell lung cancer (NSCLC). The study focuses on patients with a high suspicion of NSCLC who have had negative EBUS-TBNA results. By utilizing next generation sequencing (NGS) on the supernatant, researchers hope to gather information about lymph node involvement in cases where traditional methods have failed. This approach could potentially reduce the need for more invasive surgical procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult (age ≥18 years) patients with high suspicion for NSCLC with thoracic lymph nodes involvement (per clinical judgement and imaging studies), planned for an EBUS-TBNA procedure
* Subjects with negative EBUS-TBNA results (no evidence of lymph node involvement by tumor according to histology) who will require surgical resection of the thoracic lymph nodes will comprise the final study group

Exclusion Criteria:

1. Subjects unable or not willing to provide informed consent for study participation.
2. Subjects in whom NSCLC will ultimately be ruled out.
3. Subjects who will not require surgical resection of thoracic lymph nodes, or who will not undergo such procedure in our Medical Center for any reason

Where it's running

• Barzilai University Medical Center
  Ashkelon, Israel Recruiting

Study contacts

• Study coordinator: Ori Wand, MD
• Email: oriw@bmc.gov.il
• Phone: 97285564421

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.